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Abstract
Background: OnabotulinumtoxinA has been shown to reduce headache-days among patients with chronic
migraine (CM). The objective of this analysis was to determine whether onabotulinumtoxinA has an impact on
headache-day severity in patients with CM among those patients who were deemed non-responders based on
reduction in the frequency of headache days alone.
Methods: Data from the Phase 3 REsearch Evaluating Migraine Prophylaxis Therapy (PREEMPT) clinical trial program (a
24-week, 2-treatment cycle, double-blind, randomized, placebo-controlled, parallel-group phase, followed by a 32-week,
3-treatment cycle, open-label phase) were pooled for analysis. Patients kept a daily diary to record headache severity on
a 4-point scale (from none to severe), and a 6-domain Headache Impact Test (HIT-6) was used to determine the clinical
impact of headaches. Analysis was undertaken to assess whether the subset of patients that were headache-day
frequency non-responders at week 24 (patients with <50% reduction in headache-day frequency) experienced a
reduction in headache severity whilst receiving onabotulinumtoxinA.
Results: For headache-day frequency non-responders, significant reductions in the number of severe headache days,
average daily headache severity, pooled percentage of severe headache days and headache severity score were
observed at week 24 for patients who had received onabotulinumtoxinA compared with those who had received
placebo. The between-group differences were reduced and non-significant at week 56. Similarly, headache-day
frequency non-responders receiving onabotulinumtoxinA were found to have an improvement in the clinical impact
of headaches using results from the HIT-6.
Conclusions: These results suggest that even those patients with CM who are deemed non-responders based on
analysis of headache frequency alone experience clinically meaningful relief from headache intensity following
treatment with onabotulinumtoxinA.
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Background
Chronic migraine (CM; ≥15 headache days per month
for ≥3 consecutive months and with ≥8 days/month of
migraine-type headaches) [1] is associated with signifi-
cant personal, societal, and economic burdens [2–5].
Compared with people with episodic migraine (EM; <15
headache days per month), those with CM experience
greater headache intensity, increased pain severity and
disability, [2] higher rates of comorbid medical condi-
tions, [2, 4] reduced health-related quality of life, [2]
greater economic burden, [6] and reduced productivity.
[3, 6].
The Phase 3 REsearch Evaluating Migraine Prophylaxis
Therapy (PREEMPT) clinical trial program established
the safety and efficacy of onabotulinumtoxinA for CM
[7–10]. In PREEMPT 1 and 2, patients were randomized
to double-blind treatment with onabotulinumtoxinA or
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placebo (24 weeks), followed by open-label treatment with
onabotulinumtoxinA (32 weeks) [7–10]. Treatment with
onabotulinumtoxinA resulted in significant improvements
in a variety of efficacy endpoints, including the change in
frequency of headache days throughout the double-blind
treatment period [10]. Nevertheless, anecdotal reports
from treating clinicians have indicated that results from
these trials do not fully reflect the patient benefits that are
observed in clinical practice. Specifically, it has been sug-
gested that onabotulinumtoxinA treatment may have an
impact on other clinical characteristics such as headache-
day severity.
In this analysis, we assessed the effect of onabotuli-
numtoxinA on headache-day severity in patients with
CM using pooled data from the PREEMPT clinical trials.
Our analysis placed a particular focus on the effect on
patients who did not experience a clinically meaningful
reduction in the frequency of headache days.
Methods
Study details have been reported previously, [7, 8] and
will be only summarized here.
Study design
Briefly, PREEMPT 1 was conducted at 56 North Ameri-
can sites from January 2006 to July 2008 and PREEMPT
2 was conducted at 50 North American and 16 Euro-
pean sites from February 2006 to August 2008. The
studies consisted of a 28-day baseline screening phase,
followed by two 12-week treatment cycles over a 24-
week randomized, double-blind, placebo-controlled
phase (2 treatment cycles), and then a 32-week open-
label phase in which all patients received onabotulinum-
toxinA (3 treatment cycles).
The PREEMPT clinical trial program was conducted in
accordance with the Declaration of Helsinki and Good Clin-
ical Practice guidelines and was approved by an Independent
Ethics Committee. All patients provided written informed
consent prior to participation in the clinical trial (Clinical-
Trials.gov identifiers: NCT00156910 and NCT00168428).
This post-hoc analysis reports pooled results of both
PREEMPT 1 and PREEMPT 2 including data from the
double-blind and open-label phases of the trials (a total
of 56 weeks).
Study participants
Men and women were eligible for inclusion if they had a
history of migraine and met the International Classifica-
tion of Headache Disorders (2nd edition; [ICHD-2]) mi-
graine diagnostic criteria, with ≥15 headache days per
month (headache day was defined as a calendar day with
≥4 continuous hours of headache), of which ≥50% were
considered migraine-type headache days. Patients were
excluded from the study if they were experiencing
continuous headaches, had taken headache prophylaxis
in the 4 weeks before enrollment into the study or they
had previously been treated with a botulinum toxin.
Study treatment
Patients were randomized (1:1 in blocks of 4, stratified
by frequency of acute pain medication use during the
28-day baseline period) [7, 8] to receive either onabotuli-
numtoxinA (155 U) or placebo for the first 2 treatment
cycles. Therapy was administered via intramuscular in-
jection in fixed dosages at 31 fixed-sites across 7 specific
head and neck muscle areas. Up to 40 additional units
of onabotulinumtoxinA could be administered according
to a “follow the pain” strategy, up to a total dosage of
195 U per treatment cycle administered in up to 39 ana-
tomical sites.
Assessment of outcome measures
A patient daily telephone diary was kept using an inter-
active voice response system for the duration of the
studies including the 28-day baseline screening period.
Headache-day severity was collected on a daily basis via
the patient diary and assessed every 4 weeks.
In the PREEMPT trials, pooled safety analyses were
undertaken for all patients who received at least one
dose of onabotulinumtoxinA or placebo.
Headache-day severity
In accordance with guidance for controlled trials, [11]
the degree of headache severity was rated on a 4-point
scale to indicate severe (3), moderate (2) or mild (1), or
headache-free (0). The severity of headache days was de-
termined by the maximum severity across all the head-
ache reports for the day. For headaches that lasted >1
calendar day, the reported level of headache severity was
applied to each day that the headache lasted for any
given headache report. Diary days that were either with-
out any reported headache or with a reported headache
of <4 h continuous duration were defined as headache-
free days.
Headache-day severity outcomes assessed the change
from the baseline period in the number of days with
severe headache (as assessed from patient dairies per 28-
day period), pooled number of severe headache days (de-
fined as the sum of severe headache days reported across
all patients during the previous 28-day period), and the
severity responder analysis. A severity responder was de-
fined as a patient who achieved a ≥ 1-grade improve-
ment in average daily headache severity (ADHS) score
across the assessment period (e.g., a reduction in head-
ache severity from severe to moderate).
Headache-day severity outcomes were then assessed
among those patients who were considered headache-day
frequency “non-responders”. Headache-day frequency non-
Matharu et al. The Journal of Headache and Pain  (2017) 18:78 Page 2 of 8
responders were defined as patients with <50% reduction in
headache-day frequency from the 28-day baseline screening
period to week 24, as defined by the number of patient
diary-reported days per 28-day period with ≥4 continuous
hours of headache.
The 6-Item Headache Impact Test (HIT-6), [12, 13] a
6-domain internet-based survey, was used to assess the
impact of headaches on the patient. Response options
for each of the 6 questions were: never (scored as 6),
rarely (8), sometimes (10), very often (11), and always
(13), giving a total possible score of between 36 and 78.
If ≥50% of the questions were answered, the total score
was extrapolated from the mean score across answered
questions. If <50% of the questions were answered, the
score was set to missing.
Using the HIT-6 outcomes, patient response was ana-
lyzed. Patients who had an improvement in headache se-
verity from baseline (≥1-grade improvement in severity
from baseline) and an improvement in their HIT-6 score
of ≥5 points were considered to be “responders”, as a re-
duction in HIT-6 scores of ≥5 points from baseline has
previously been defined as clinically meaningful [14, 15].
Statistical analyses
Headache-day severity
We assessed the change from baseline in the number of
severe headache days. Missing counts were estimated
using modified last observation carried forward (mLOCF)
techniques. P-values for between-treatment comparisons
were calculated using covariate analysis of variance
(ANCOVA), with baseline values as the covariate. The
main effects in the ANCOVA included treatment and
medication-overuse strata, where the type III sum of
squares was used.
Statistics were calculated for the number of severe
headache days pooled across patients for each time
period. Any missing time period data for a patient were
estimated using mLOCF. Between-treatment compari-
sons of the percentage of severe headache days were de-
termined by Pearson’s chi-square or Fisher’s exact tests
(for this parameter and for others discussed below, if
≥25% of the expected cell counts were <5) for each
headache-day severity category.
ADHS scores were the average severity score, as
assessed by the patient, across all reported diary days,
weighted to account for headache days without severity
report and rounded to the nearest whole number. Im-
provement of ≥1 grade in ADHS (e.g. from severe to mod-
erate) included patients with score reduction of at least 1.
Statistics were calculated for the change from the baseline
severity score. Missing values were estimated using
mLOCF. Between-treatment comparisons of the percent-
age of patients with ≥1-grade improvement in ADHS were
determined by Pearson’s chi-square or Fisher’s exact tests.
HIT-6 responder analysis
Similarly, statistics were calculated for baseline and
change from baseline for HIT-6 scores to categorize
HIT-6 responders, defined as patients with ≥5-point im-
provement in HIT-6 scores from baseline. For various
time periods in the subset of headache-day frequency
non-responders, whose headaches had reduced in sever-
ity by at least 1 grade by week 24, between-treatment
comparisons of HIT-6 responders were determined by
Pearson’s chi-square or Fisher’s exact tests.
Results
Patient disposition and demographics
A total of 1384 patients received either onabotulinum-
toxinA (n = 688) or placebo (n = 696) in the 24-week
double-blind phase before receiving onabotulinumtox-
inA in the open label phase. Baseline demographic and
clinical characteristics were similar between the two
overall treatment groups (Table 1). The mean patient
age at baseline was 41 years, and the mean duration
since the onset of CM was 19 years. More than 85% of
the patients in both groups were female and more than
60% of patients were using prophylactic medications for
migraine prior to enrollment into the study. Patient dis-
continuation across the 56-week study was 25.4% and
29.3% for the onabotulinumtoxinA and placebo study
arms, respectively, with no major differences in the rea-
sons for withdrawal from the study (Fig. 1).
Of the 645 patients that were classified as non-
responders at week 24 (i.e. had <50% reduction in
headache-day frequency), 285 patients had received onabo-
tulinumtoxinA and 360 patients had received placebo.
There were no statistically significant differences in the
baseline demographic and clinical characteristics between
the 2 non-responder groups (Table 1). The non-responder
groups were also largely similar to the overall population;
although a slightly higher percentage of the non-responders
used prophylactic medications at baseline.
Changes in headache severity in headache-day frequency
non-responders
Among those with a less than 50% reduction from base-
line in headache-day frequency at week 24 (headache-day
frequency non-responders), reduction from baseline in the
number of severe headache days per 28-day period was
significantly greater when treated with onabotulinumtox-
inA compared with placebo throughout the 24-week
double-blind period (Fig. 2). These between-group differ-
ences decreased and were no longer significant in the
open-label phase of the study.
In addition, in headache-day frequency non-
responders, the percentage of severe headache days
pooled across patients was significantly lower through-
out the 24-week double-blind period for those treated
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with onabotulinumtoxinA than those receiving placebo
(Fig. 3). These between-group differences decreased dur-
ing the open-label phase of the trial when both groups
of patients received onabotulinumtoxinA and the differ-
ences were no longer significant by week 40.
Patients who had at least a 1-grade improvement from
baseline in the severity of their headaches based on patient
diaries were considered to be severity responders. Among
headache-day frequency non-responders, significant re-
ductions in the severity of the headaches occurred more
frequently in patients receiving onabotulinumtoxinA than
in patients receiving placebo at week 24 (41.1% vs 31.4%;
P = 0.011; Table 2). Once all patients were receiving ona-
botulinumtoxinA in the open-label phase of the trial,
between-group differences disappeared and were not sig-
nificant at week 56 (64.6% vs 65.6%; P = 0.792).
Analysis based on HIT-6 scores
Separate analysis was undertaken to assess whether
HIT-6 scores demonstrated a positive response to
treatment (≥5-point increase in HIT-6 scores from base-
line, as has previously been deemed to be a positive
response to treatment [14, 15]) in patients whose head-
aches reduced in severity (≥1 grade change in severity).
The results were similar to those reported above. At
week 24, HIT-6 responder rates were significantly higher
for onabotulinumtoxinA than for placebo (62.2% vs
43.5%; P < 0.001), and at week 56, the response rates
were similar between treatment groups (74.4% vs 72.0%;
P = 0.601; Table 2).
Safety
The results of the PREEMPT trials previously published
confirmed that onabotulinumtoxinA is safe and well tol-
erated for the long-term prophylactic treatment of CM
[9]. Treatment-related adverse events (TRAEs) were
consistent with the known safety profile of onabotuli-
numtoxinA. In the double- blind phase of the study,
neck pain (6.7%), muscular weakness (5.5%), eyelid pto-
sis (3.3%), injection-site pain (3.2%), headache (2.9%),
Table 1 Baseline demographic and clinical characteristics for overall PREEMPT group and the non-responder subgroupa
Characteristic Overall PREEMPT Group Non-Responder Subgroup
O/O (n = 688) P/O (n = 696) P-valueb O/O (n = 285) P/O (n = 360) P-valueb
Mean (SD) age, y 41.1 (10.4) 41.5 (10.7) 0.58 42.3 (10.4) 42.8 (10.5) 0.56
Age ≥ 40 y, n (%) 395 (57.4) 408 (58.6) 0.65 179 (62.8) 224 (62.2.) 0.94
Sex, n (%)
Female 603 (87.6) 593 (85.2) 0.19 242 (84.9) 309 (85.8) 0.74
Race/Ethnicity, n (%) 0.60 0.40
White 617 (89.7) 630 (90.5) 257 (90.2) 333 (92.5)
Black 34 (4.9) 40 (5.7) 15 (5.3) 17 (4.7)
Hispanic 27 (3.9) 19 (2.7) 9 (3.2) 9 (2.5)
Other 10 (1.5) 7 (1.0) 4 (1.4) 1 (0.3)
Mean (SD) age of onset of CM, y 21.2 (11.0) 21.9 (11.9) 0.46 21.3 (11.4) 22.5 (12.1) 0.19
Mean (SD) CM duration, y 19.4 (12.4) 19.0 (12.7) 0.49 20.4 (12.2) 19.7 (12.8) 0.46
Mean (SD) headache days (≥4 h) per 28-day period 19.9 (3.7) 19.8 (3.7) 0.52 20.5 (3.9) 20.4 (4.0) 0.61
Prestudy headache prophylactic use, n (%) 425 (61.8) 454 (65.2) 0.18 197 (69.1) 263 (73.1) 0.29
Acute headache medicine overuse, n (%) 446 (64.8) 460 (66.1) 0.62 195 (68.4) 251 (69.7) 0.73
Mean (SD) HIT-6 scorec 65.5 (4.1) 65.4 (4.3) 0.64 65.4 (3.8) 65.3 (4.4) 0.84
Patients with severe headache impact
(HIT-6 total score ≥ 60), %c 93.5 92.7 0.57 93.7 92.8 0.75
Mean (SD) MSQ scored
Role restrictive 38.5 (16.6) 38.7 (17.3) 0.97 37.9 (16.7) 38.4 (17.5) 0.67
Role preventive 56.0 (21.2) 56.1 (21.7) 0.83 57.0 (21.9) 56.1 (21.7) 0.62
Emotional functioning 42.1 (24.1) 42.4 (25.0) 0.81 42.7 (23.6) 44.6 (24.7) 0.31
CM chronic migraine, HIT-6 6-item Headache Impact Test, MSQ Migraine-Specific Quality of Life Questionnaire, O/O onabotulinumtoxinA in double-blind phase and
open-label phase, P/O placebo in double-blind phase and onabotulinumtoxinA in open-label phase, PREEMPT Phase 3 REsearch Evaluating Migraine
Prophylaxis Therapy
aNonresponder group = <50% reduction in headache-day frequency at week 24
bP-values are the pairwise t-test or the Fisher’s exact test between the O/O vs the P/O groups for each respective population group
cHIT-6 scores of 36–49 indicate little or no impact; 50–55, some impact; 56–59, substantial impact; 60–78, severe impact
dMSQ v2.1 scores range from 0 (poor) to 100 (good)
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myalgia (2.6%), musculoskeletal stiffness (2.3%), and
musculoskeletal pain (2.2%) were reported by ≥2% of pa-
tients receiving onabotulinumtoxinA. TRAE decreased
in the open-label phase of the study with neck pain
(4.6%), muscular weakness (3.9%), eyelid ptosis (2.5%),
muscle tightness (2.2%) and injection site pain (2.0%) the
only TRAEs occurring in ≥2% of patients. Serious
TRAEs were rare occurring in 1 patient (0.1%) in both
the double-blind and open-label phases of the PRE-
EMPT trials.
Discussion
In an earlier analysis of the PREEMPT data, it was observed
that 49% of patients treated with onabotulinumtoxinA
Fig. 1 Patient Disposition. Reproduced with permission from Aurora, et al. Headache 2011;51:1358–73
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demonstrated a ≥ 50% reduction in headache-day frequency
after 1 treatment cycle, and an additional 11% who did not
respond after the first treatment cycle responded after treat-
ment cycle 2 [16]. In the current analysis, we present data
for the effect of onabotulinumtoxinA on headache-day se-
verity among those with CM who did not have a reduction
in headache-day frequency after two cycles of treatment
(non-responders defined as <50% reduction in headache-
day frequency at week 24). During the randomized,
placebo-controlled, double-blind phase, patients treated
with onabotulinumtoxinA demonstrated a greater reduction
from baseline in the number of severe headache days per
28-day period than did those receiving placebo. In addition,
compared with the placebo group, there were a lower per-
centage of patients receiving onabotulinumtoxinA with an
ADHS score of severe, a lower percentage of severe head-
ache days pooled across all patients within the onabotuli-
numtoxinA group, and a higher rate of at least 1-grade
improvement in headache severity from baseline (severity
responders). Among all severity responders, the proportion
of HIT-6 responders (≥5-point improvement from baseline)
was greater for the onabotulinumtoxinA group than the pla-
cebo group at the end of the double-blind phase.
The headache-day severity endpoints showed a note-
worthy peak at week 24 in both onabotulinumtoxinA
and placebo treatment groups. The key reason for this
non-response peak is the selection criteria, since the
population of interest was predefined as those without
adequate treatment response in relation to headache-day
frequency at week 24. It is interesting that in this group
of non-responders, there was some response at other
time points both before the arbitrary 24-week non-
response point and after that time point.
Open-label results where both groups were receiving
onabotulinumtoxinA generally demonstrated lesser
between-group differences, with no significant differ-
ences between the groups observed by the end of the
56-week study. Conversely, headache-day frequency, as
previously reported by Aurora et al., [9] was significantly
reduced by onabotulinumtoxinA in the double-blind
phase and continued to show between-group differences
through to week 56, making a case for early treatment
with onabotulinumtoxinA in patients with CM. This ob-
servation suggests that treatment with onabotulinumtox-
inA produces significant reduction in headache-day
severity that may compliment a reduction in headache-
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Table 2 Severity and HIT-6 Responder Analysis
Proportion of severity responders, among headache-day frequency non-respondersa
OnabotulinumtoxinA/ OnabotulinumtoxinA n = 285 Placebo / OnabotulinumtoxinA n = 360 P-value
Week 24 41.1% 31.4% 0.011
Week 56 64.6% 65.6% 0.792
Proportion of HIT-6 responders, among severity respondersb
OnabotulinumtoxinA/ OnabotulinumtoxinA n = 246 Placebo / OnabotulinumtoxinA n = 161 P-value
Week 24 62.2% 43.5% <0.001
Week 56 74.4% 72.0% 0.601
HIT-6 6-item Headache Impact Test
aPatients with severity response (≥1-grade improvement from baseline in severity), among patients with <50% reduction from baseline in headache-day frequency
at week 24
bPatients with a HIT-6 response (≥5-point improvement from baseline), among patients with ≥1-grade reduction from baseline in headache-day severity at
week 24
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day frequency, since onabotulinumtoxinA treatment in
the open-label phase was able to eliminate between-
group differences in severity, but not frequency. These
findings are worthy of further investigation to fully
understand the potential therapeutic benefit of early
treatment with onabotulinumtoxinA.
Importantly, the current analysis demonstrated reduced
headache-day severity at the first post-baseline assessment
(week 4) in patients who were headache-day frequency
non-responders at week 24, suggesting an important clin-
ical response to treatment not captured by the measure of
headache-day frequency reduction. Furthermore, the
alignment of the HIT-6 response with the severity re-
sponse suggests that the reduction in headache-day sever-
ity of at least 1 grade was clinically meaningful. Further
study is required to determine whether this clinical re-
sponse translates into a reduction in healthcare resource
utilization and broader economic benefits.
The large number of patients with CM included in
these double-blind placebo-controlled studies makes
these results particularly robust. The use of the voice
interactive daily telephone diary encouraged high patient
compliance with diary record keeping and captured data
without the need for reliance on long-term recall. This
would be expected to result in more accurate capture of
patient data, as others have shown that current health
status can have an impact upon a patient’s recollection
of the past [17].
The study is not without its limitations. The lack of an
active comparator is a potential limitation. However, the
lack of any approved prophylactic treatment for CM
makes it difficult to identify an appropriate comparator.
The time point to determine headache-day frequency
nonresponse was set at week 24, which was an arbitrary
time point. The selection of a different time point for
the definition of non-response may have resulted in dif-
ferent outcomes. Further clinical trials may be required
to understand if a different time point for the determin-
ation of headache-day frequency non-response has any
clinically meaningful impact on the interpretation of the
data presented here.
Similarly, no optimal responder rate for the reduction
from baseline in headache-day frequency has been de-
fined for the CM population. Although both 30% and
50% cutoffs for headache measures have been suggested
to be clinically meaningful, [11] a 50% cutoff is more
commonly used in migraine studies, and provided the
rationale for the definition of non-responders for the
current analysis. Analysis of the current data using
a <30% reduction in headache-day frequency as the def-
inition for non-response produced similar results to
those reported here, with those classified as non-
responders achieving a significant reduction in headache
severity (Additional file 1: Table S1, and Figures S1 and
S2). This additional analysis using <30% as the cutoff
further strengthens the findings of this analysis.
The International Headache Society has published
guidelines for clinical trial assessment of prophylactic
treatment for CM, including guidelines on the selection
of outcome measures [11]. The primary end-point out-
comes recommended by these international experts in-
clude headache days with moderate or severe intensity,
migraine days, or frequency of migraine episodes. How-
ever, despite this international accord on the selection of
outcome measures to encourage robust clinical trials,
the outcomes may not fully align with the patient’s ex-
pectation of therapy. This study demonstrates that fre-
quency day response alone may not be sufficient to
determine a clinically meaningful response to therapy,
and highlights the need for further work on developing
key patient-endorsed outcome measures for the assess-
ment of prophylactic treatment of chronic migraine in
particular and headache disorders in general.
Conclusions
Patients from the PREEMPTclinical trial program who re-
ceived onabotulinumtoxinA and met our definition for
headache-day frequency non-response (<50% reduction in
headache-day frequency at week 24) demonstrated signifi-
cantly reduced headache-day severity (compared with
those receiving placebo). Among those who showed re-
duced headache-day severity, onabotulinumtoxinA also
produced greater reduction in headache impact scores.
These results suggest that patients with CM experience
clinically meaningful relief from headache intensity follow-
ing treatment with onabotulinumtoxinA, even among
those who may not experience a clinically meaningful re-
duction in the frequency of their headaches.
Additional file
Additional file 1: Table S1. Percentage of patients with a measurable
change in headache severity among patients with <30% reduction in
headache-day frequency. Figure S1. Change from baseline in the number
of severe headache days per 28-day period, among patients with <30%
reduction in headache-day frequency. *P<0.001, †P<0.05. Figure S2.
Percentage of severe headache days, pooled across patients with <30%
reduction in headache-day frequency. *P<0.001, †P<0.05. (PDF 35 kb)
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